CORRESP Filing
GridAI Technologies Corp.
Date: Sept. 10, 2025 · CIK: 0001604191 · Accession: 0001104659-25-089121
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287185, 333-289864
Referenced dates: September 5, 2025
Letter
Entero Therapeutics, Inc.
777 Yamato Road, Suite 502
Boca Raton, Florida 33431
September 10, 2025
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, D.C. 20549
Attn: Jason Drory and Laura Crotty
Re: Entero Therapeutics, Inc.
Registration Statement on Form S-1
Submitted on August 26, 2025
File No. 333-289864
Ladies and Gentlemen:
On behalf of Entero Therapeutics, Inc. (the "Company"), please find below responses to comments provided by the staff (the "Staff") of the Securities and Exchange Commission (the "Commission") in its comment letter dated September 5, 2025, relating to the Company's Registration Statement on Form S-1 filed on August 26, 2025. Amendment No. 1 to the Company's Registration Statement revises the Registration Statement filed on August 26, 2025 to reflect the Company's responses to the comment letter dated September 5, 2025.
The Company's responses are numbered to correspond to the Staff's comments. For your convenience, each of the Staff's comments contained in the comment letter have been restated and are followed by the Company's responses.
Registration Statement on Form S-1 filed August 26, 2025
Prospectus Summary
Our Product Candidates, page 8
1. We note your disclosure on page 8 where you refer to a contemplated "offering under the registration statement on Form S-1 (file number: 333-287185)." Please revise your disclosure to clarify the registration statement you reference has not been declared effective and you have not raised any proceeds from the offering.
Response:
In response to the Staff's comment, the Company has revised the disclosure on page 8 to clarify that the registration statement on Form S-1 (file number: 333-287185) has not been declared effective and that the Company has not raised any proceeds from the offering. The Company has also revised the disclosure on page 12 to make a similar clarification in reference to the registration statement on Form S-1 (file number: 333-287185).
Should you have additional questions or require any clarification regarding the information contained herein or in the Registration Statement, please contact the undersigned at Ross Carmel, Esq., rcarmel@srfc.law , or Avital Perlman, Esq. at aperlman@srfc.law .
Very truly yours,
By:
/s/ Jason
D. Sawyer
Show Raw Text
CORRESP 1 filename1.htm Entero Therapeutics, Inc. 777 Yamato Road, Suite 502 Boca Raton, Florida 33431 September 10, 2025 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Jason Drory and Laura Crotty Re: Entero Therapeutics, Inc. Registration Statement on Form S-1 Submitted on August 26, 2025 File No. 333-289864 Ladies and Gentlemen: On behalf of Entero Therapeutics, Inc. (the "Company"), please find below responses to comments provided by the staff (the "Staff") of the Securities and Exchange Commission (the "Commission") in its comment letter dated September 5, 2025, relating to the Company's Registration Statement on Form S-1 filed on August 26, 2025. Amendment No. 1 to the Company's Registration Statement revises the Registration Statement filed on August 26, 2025 to reflect the Company's responses to the comment letter dated September 5, 2025. The Company's responses are numbered to correspond to the Staff's comments. For your convenience, each of the Staff's comments contained in the comment letter have been restated and are followed by the Company's responses. Registration Statement on Form S-1 filed August 26, 2025 Prospectus Summary Our Product Candidates, page 8 1. We note your disclosure on page 8 where you refer to a contemplated "offering under the registration statement on Form S-1 (file number: 333-287185)." Please revise your disclosure to clarify the registration statement you reference has not been declared effective and you have not raised any proceeds from the offering. Response: In response to the Staff's comment, the Company has revised the disclosure on page 8 to clarify that the registration statement on Form S-1 (file number: 333-287185) has not been declared effective and that the Company has not raised any proceeds from the offering. The Company has also revised the disclosure on page 12 to make a similar clarification in reference to the registration statement on Form S-1 (file number: 333-287185). Should you have additional questions or require any clarification regarding the information contained herein or in the Registration Statement, please contact the undersigned at Ross Carmel, Esq., rcarmel@srfc.law , or Avital Perlman, Esq. at aperlman@srfc.law . Very truly yours, By: /s/ Jason D. Sawyer Jason D. Sawyer Interim Chief Executive Officer cc: Ross Carmel, Esq. Avital Perlman, Esq.